We noted a trend, although not statistically significant, of an increased incidence of CIP among former and current smokers, high PD-L1 expressers, squamous histology, patients with COPD, and those receiving pembrolizumab-based therapy. This evidence concerns the gene CD274 and hereditary sensory and autonomic neuropathy.